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ofOBJECTIVES The aim of this study was to evaluate the pathophysiological features and response to primary percu-
taneous coronary intervention (PCI) of nonruptured/eroded plaque versus ruptured plaque as a cause of ST-segment
elevation myocardial infarction (STEMI).
BACKGROUND Autopsy series identiﬁed nonruptured/eroded plaque and ruptured plaque as the principal pathological
substrates underlying coronary thrombosis in STEMI. The real incidence of different plaque morphologies, associated
biological factors, superimposed thrombus, and their interaction with primary PCI remain largely unknown.
METHODS In a prospective study, 140 patients with STEMI underwent optical coherence tomography of the infarct-
related artery (IRA) before PCI, after everolimus-eluting stent implantation and at 9-month follow-up. Histopathology
and immunohistochemistry of thrombus aspirates and serum biomarkers were assessed at baseline.
RESULTS Culprit plaque morphology was adjudicated in 97 patients: 32 plaques (33.0%) with an intact ﬁbrous cap
(IFC), 63 (64.9%) plaques with a ruptured ﬁbrous cap (RFC), and 2 (2.1%) spontaneous dissections. Patients with an IFC
and RFC had similar clinical characteristics, and serum inﬂammatory and platelets biomarkers. An IFC presented more
frequently with a patent IRA (56.2% vs. 34.9%; p ¼ 0.047), and had fewer lipid areas (lipid-rich areas: 75.0% vs.
100.0%; p < 0.001) and less residual thrombus before stenting (white thrombus: 0.41 mm3 vs. 1.52 mm3; p ¼ 0.001;
red thrombus: 0 mm3 vs. 0.29 mm3; p ¼ 0.001) with a lower peak of creatine kinase-myocardial band (66.6 IU/l vs.
149.8 IU/l; p ¼ 0.025). At the 9-month optical coherence tomography, IFC and RFC had similar high rates of stent
strut coverage (92.5% vs. 91.2%; p ¼ 0.15) and similar percentage of volume obstruction (12.6% vs. 10.2%; p ¼ 0.27).
No signiﬁcant differences in clinical outcomes were observed up to 2 years.
CONCLUSIONS In the present study, an IFC was observed at the culprit lesion site of one-third of STEMIs. IFC,
compared with RFC, was associated with higher rates of patent IRA at ﬁrst angiography, fewer lipid areas, and residual
endoluminal thrombus. However, no difference in vascular response to everolimus-eluting stent was observed.
(Optical Coherence Tomography Assessment of Gender Diversity in Primary Angioplasty [OCTAVIA]; NCT01377207)
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AND ACRONYM S
CSA = cross-sectional area
EES = everolimus-eluting stent
IFC = intact ﬁbrous cap
IRA = infarct-related artery
MPO = myeloperoxidase
OCT = optical coherence
tomography
PCI = percutaneous coronary
intervention
RFC = ruptured ﬁbrous cap
STEMI = ST-segment elevation
myocardial infarction
TCFA = thin-cap ﬁbroatheroma
TIMI = Thrombolysis In
Myocardial Infarction
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567T he cornerstone of ST-segment elevation acutemyocardial infarction (STEMI) treatment israpid ﬂow restoration with primary angio-
plasty and stenting (1,2). Autopsy series showed that
plaques underlying coronary thrombi in acute myo-
cardial infarction may have different features, and
the most common phenotypes are plaque rupture
and plaque erosion (3). The potential impact of
different culprit plaque characteristics in STEMI pa-
tients undergoing revascularization remains a matter
of debate (4), but different plaquemorphologies might
be potentially amenable to different treatments (5). A
tailored approach to STEMI treatment would require
improved understanding of atherothrombosis, as
well as the ability to distinguish in vivo various plaque
morphologies. Finally, it remains unknown whether
different plaque types might elicit a distinct vascular
response to stent implantation.SEE PAGE 576Postmortem data highlighted that a ruptured pla-
que is by far the most common cause of coronary
thrombosis in acute myocardial infarction (3,6).
Conversely, nonruptured/eroded plaque, the second
cause of coronary thrombosis in ex vivo series, is
characterized by endoluminal thrombosis without
evidence of plaque rupture in serial sectioning of the
arterial segment (3,6–8). However, pathology studies
are limited by the potential patient selection bias, and
they cannot assess the impact of plaque phenotypes
on the results of coronary interventions. Therefore, in
patients presenting with STEMI, the incidence, the
biological characteristics, and the clinical impact
associated with different culprit plaque morphologies
remain unclear.
Optical coherence tomography (OCT) in patients
with acute coronary syndromes allows accurate
in vivo detection and measurements of culprit pla-
que with intact ﬁbrous cap (IFC) and with ruptured
ﬁbrous cap (RFC), intracoronary thrombus, thin-cap
ﬁbroatheroma (TCFA), and the healing responseVascular, Eli Lilly, AstraZeneca, and St. Jude Medical; and speaker fees fro
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lated with pathology (9). In patients with
STEMI, OCT has been shown to be safe and
superior to other intravascular imaging
modalities for plaque differentiation (10,11).
The objectives of this prospective, multi-
center study in patients presenting with
STEMI were the following: 1) to deﬁne the
incidence of different culprit plaque mor-
phologies detected by OCT in clinical practice;
2) to assess clinical characteristics, plaque
features, and serum components associated
with IFC compared with RFC; and 3) to com-
pare the acute and chronic vascular response
to current-generation drug-eluting stents
implanted in patients with IFC versus RFC.
METHODSSTUDY DESIGN AND POPULATION. The present
study, which focused on the comparison of patients
presenting with IFC versus RFC at the culprit site of
STEMI, represents a pre-speciﬁed analysis of the
OCTAVIA (Optical Coherence Tomography Assess-
ment of Gender Diversity in Primary Angioplasty) trial
(12). The full study design and methodology were
previously reported (12). In brief, the OCTAVIA trial
was a prospective, multicenter, investigator-driven
trial that enrolled 140 STEMI patients presenting
within 6 h of symptom onset. All patients underwent
primary percutaneous coronary intervention (PCI)
and received the Xience Prime everolimus-eluting
stent (EES) (Abbott Vascular, Santa Clara, Califor-
nia). The study was approved by the ethics committee
at each participating center, and all enrolled patients
provided written informed consent. For a list of
the OCTAVIA Study Organization, please see the
Online Appendix.
STUDY PROCEDURES. OCT pullback of the infarct-
related artery (IRA) was performed before PCI,
using a Frequency Domain OCT system (C7-XRTMm Abbott Vascular, Eli Lilly, AstraZeneca, St. Jude
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568OCT Intravascular Imaging System, St. Jude Medical,
St. Paul, Minnesota). If Thrombolysis In Myocar-
dial Infarction (TIMI) ﬂow grade 0/1 or extensive
thrombus was present at baseline, the OCT pullback
was performed after manual thrombectomy. PCI was
then performed according to local practice, and all
patients received 1 or more EES. Aspirin 250 mg was
given intravenously immediately before PCI, fol-
lowed by 100 mg/day orally during hospitalization
and indeﬁnitely thereafter. A loading dose of clopi-
dogrel (600 mg) or prasugrel (60 mg) was adminis-
tered at the operator’s discretion before PCI followed
by a 75-mg (clopidogrel) or 10-mg (prasugrel) oral
maintenance dose daily for 12 months. Clinical ex-
aminations were performed at 30 days, 9 months, and
1 and 2 years. Angiographic and OCT follow-up at
9 months after stent implantation was electively
planned in all patients.
OCT ANALYSIS. All OCT images were analyzed by
an independent core laboratory (Cardiovascularow
ence tomography; PCI ¼ percutaneous coronary intervention; pts ¼ patients;
cardial Infarction.Imaging Core Laboratory, University Hospitals Case
Medical Center, Cleveland, Ohio) using previously
standardized criteria (13–16). Qualitative analysis
was performed every 0.2 mm along the entire
target segment. RFC was deﬁned by the presence
of a cavity formation in the plaque beginning at
the luminal-intimal border with a clear disconti-
nuity of the thin ﬁbrous cap; IFC was deﬁned by
no evidence of cap rupture at the culprit site,
evaluated in multiple adjacent frames, and the
presence of thrombus on an irregular luminal sur-
face; spontaneous dissection was identiﬁed by the
presence of an intimal-medial ﬂap with intramural
hematoma; plaque morphology was deﬁned un-
classiﬁable when OCT was unable to distinguish
the lesion type because of an excess of thrombus
obscuring the underlying structures. Each OCT
cross section was divided into 4 quadrants, and
culprit plaques were classiﬁed as calciﬁed, ﬁbrous,
or lipid rich when these components were presentSTEMI ¼ ST-segment elevation myocardial infarction; TIMI ¼
TABLE 1 Baseline Clinical Characteristics
IFC
(n ¼ 32)
RFC
(n ¼ 63) p Value
Age, yrs 69.5 (59.0–74.5) 68.0 (60.0–76.0) 0.77
Male 16 (50.0) 32 (50.8) 0.94
BMI 26.7 (23.6–30.1) 26.0 (24.2–29.7) 0.78
Hypertension 18 (56.2) 34 (54.0) 0.83
Dyslipidemia 8 (25.0) 18 (28.6) 0.71
Smoking 18 (56.2) 33 (52.4) 0.72
Diabetes 4 (12.5) 6 (9.5) 0.73
Insulin-treated 2 (6.2) 0 (0.0) 0.11
Previous MI 0 (0.0) 1 (1.6) 1.00
Previous angina 4 (12.5) 4 (6.3) 0.44
Time from symptom onset
to cath lab, min
153 (124–229) 140 (95–195) 0.09
Peak CK-MB, IU/l 66.6 (33.3–141.4) 149.8 (52.9–230.0) 0.025
Values are median (interquartile range) or n (%).
BMI ¼ body mass index; CK-MB ¼ creatine kinase-myocardial band; IFC ¼ intact ﬁbrous cap; MI ¼ myocardial
infarction; RFC ¼ ruptured ﬁbrous cap.
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569in $2 contiguous quadrants in any of the images
within a plaque (12,14). If 2 adjacent quadrants
fulﬁlled the criteria for 1 component and the other
2 adjacent quadrants fulﬁlled the criteria for an-
other plaque component, plaque composition was
attributed to both components. TCFA was deﬁned
as a lipid-rich plaque with a thin ﬁbrous cap thick-
ness <65 mm, and the mean cap thickness was
computed as the mean of 3 evenly distributed mea-
surements along the ﬁbrous cap. Quantitative OCT
analyses were performed using dedicated software
(OCT system software B.0.1, LightLab Imaging Inc.,
Westford, Massachusetts). For red thrombus quan-
tiﬁcation, due to the limitations imposed by intense
backscattering and signal attenuation, a careful
analysis of adjacent frames, each 0.2 mm, was per-
formed. Whenever the inmost thrombus border
could not be identiﬁed, anchor points were posi-
tioned at the deepest identiﬁable side edges, and
automatic software interpolation was used for
determination of the thrombus border.
For morphometric analysis, standard deﬁnitions
of cross-sectional area (CSA) were applied as previ-
ously reported (16). Proximal and distal references
were measured at the site with the largest lumen
within 5 mm proximal and distal to the lesion/stented
segment. Stent, lumen, and neointimal hyperplasia
CSA were measured each 0.6 mm throughout the
entire length of the stent. The minimal stent CSA
divided by the average of proximal and distal refer-
ence lumen CSA ratio was calculated as a parameter
of stent expansion.
For the strut-level analysis, the strut-lumen
distance was determined based on automated
measurements performed from the center of the
strut blooming to the luminal contour of the artery
wall. Incomplete strut apposition was deﬁned when
this distance was greater than the sum of strut
thickness plus the abluminal polymer thickness
according to stent manufacturer speciﬁcations plus
a compensation factor of 18 mm to correct for strut
blooming. Struts were considered covered by OCT
if tissue could be identiﬁed above the struts and
uncovered if no evidence of tissue could be visual-
ized above the struts. The percentage of covered and
uncovered stent struts was calculated as the number
of struts with or without distinct overlying tissue,
respectively, divided by the total number of analyz-
able struts.
THROMBUS ANALYSIS. Thrombus aspirates were
sent to the histopathology core laboratory (CV Path
Institute, Gaithersburg, Maryland) (12,17). All sec-
tions were examined by light microscopy for thepresence of platelets, ﬁbrin, red blood cells, plaque
constituents, and markers of inﬂammation. Five
high-power ﬁelds (400) demonstrating the greatest
severity of inﬂammation were selected for semi-
quantitative analyses. The mean values of total white
blood cells and positive cells based on immunohis-
tochemistry were obtained and averaged for the
selected 5 high-power ﬁelds. Additionally, immuno-
histochemical staining including the granulocyte
marker myeloperoxidase (MPO), CD68 (macro-
phages), and the eosinophil marker interleukin 5 was
performed to further characterize speciﬁc inﬂamma-
tory cell types. A CD42b stain was used for the
detection of platelets.
SERUM BIOMARKERS. Blood samples were collected
before baseline coronary angiography, stored at 80,
and sent to the core laboratory (Institute of Cardi-
ology, Catholic University of the Sacred Heart, Rome,
Italy) for analysis. Serum C-reactive protein, MPO,
eosinophil cationic protein, and thromboxane B2 were
measured as previously described (12).
CLINICAL OUTCOMES. Major adverse cardiac or
cerebrovascular events, including cardiac death,
recurrent myocardial infarction, stroke, target-lesion
revascularization, and stent thrombosis, were as-
sessed at 30 days and 1 and 2 years. Stent thrombosis
was deﬁned according to the Academic Research
Consortium classiﬁcation (18).
STATISTICAL ANALYSIS. Continuousdata are reported
as mean  SD or median (ﬁrst to third quartiles, depend-
ing on validity or lack of normality assumptions).
Categorical data are reported as numbers and relative
percentage. Overall comparisons across groups were
based on the Student t test for continuous variables
TABLE 2 Angiograph
Infarct-related artery
LAD
LCX
RCA
Culprit lesion site
Proximal
Mid-vessel
Distal vessel
Multivessel coronary d
Thrombus aspiration
TIMI ﬂow grade at pre
0/1
2/3
Stent diameter, mm
Stent length, mm
Post-dilation
Final TIMI ﬂow grade
0/1
2
3
Baseline QCA
Reference vessel dia
Minimal lumen diam
DS, %
Lesion length, mm
QCA post-procedure
Reference vessel dia
Minimal lumen diam
DS, %
9-month QCA
Reference vessel dia
Minimal lumen diam
DS, %
Late lumen loss, mm
Values are n (%) or median
DS ¼ diameter stenosis;
tative coronary analysis; R
breviations as in Table 1.
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570(or the Mann-Whitney U test in case of signiﬁcant
departures from normality assumptions, i.e., p < 0.05
on the Kolmogorov-Smirnov or Shapiro-Wilks test) and
the chi-square test for categorical variables (or the Fisher
exact test when an expected cell count was <5). In
addition, variability in strut coverage and other quanti-
tative OCT parameters was appraised by means of the
Brown-Forsythe test for equality of variances. Event-free
survival was estimated with Kaplan-Meier analysis, and
the log-rank method was used for comparison between
groups. All tests were 2 sided, and statistical signiﬁcance
was deﬁned as p < 0.05. The interobserver and
intraobserver kappa statistics for the qualitative
assessment of plaque rupture/erosion were 0.845 (95%
conﬁdence interval: 0.769 to 0.921; p < 0.001) and 0.907ic and Procedural Characteristics
IFC
(n ¼ 32)
RFC
(n ¼ 63) p Value
0.95
15 (46.9) 28 (44.5)
2 (6.2) 6 (9.5)
15 (46.9) 29 (46.0)
0.76
9 (28.1) 21 (33.3)
15 (46.9) 30 (47.6)
8 (25.0) 12 (19.0)
isease 14 (43.8) 37 (58.7) 0.17
26 (81.2) 56 (88.9) 0.35
sentation 0.047
14 (43.8) 41 (65.1)
18 (56.2) 22 (34.9)
3.0 (2.0–4.0) 3.0 (2.0–4.0) 0.85
22.1 (17.2–26.5) 22.3 (17.4–31.0) 0.65
19 (59.4) 35 (55.6) 0.72
1.00
0 (0.0) 0 (0.0)
1 (3.1) 3 (4.8)
31 (96.9) 60 (95.2)
meter, mm 2.63  0.56 2.66  0.55 0.79
eter, mm 0.25 (0.00–0.50) 0.00 (0.00–0.54) 0.58
88 (77–100) 100 (80–100) 0.54
13.0 (10.0–17.2) 13.5 (9.4–20.9) 0.99
meter, mm 2.83  0.56 2.73  0.50 0.40
eter, mm 2.48 (2.24–3.10) 2.35 (2.10–2.75) 0.28
8.0 (4.0–12.0) 10.0 (6.5–14.0) 0.36
meter, mm 2.57  0.56 2.56  0.49 0.96
eter, mm 2.00 (1.52–2.55) 1.96 (1.50–2.34) 0.66
19.0 (9.0–29.0) 22.0 (13.0–32.5) 0.50
0.20 (0.03–0.40) 0.22 (0.06–0.44) 0.66
(interquartile range).
LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery; QCA ¼ quanti-
CA ¼ right coronary artery; TIMI ¼ Thrombolysis In Myocardial Infarction; other ab-(95% conﬁdence interval: 0.781 to 1.00; p < 0.001),
respectively. The core laboratory relative difference for
the quantitative OCT endpoints was w1%, as previously
reported (15).
RESULTS
PATIENTS AND BASELINE FEATURES. All 140 pa-
tients enrolled in the study had OCT assessment
before primary PCI (Figure 1). A total of 12 patients
were not further classiﬁed because OCT did not
satisfy the pre-speciﬁed quality criteria (12). In 31
patients, culprit lesion morphology could not be
clearly attributed because of excessive residual
intraluminal thrombus (n ¼ 22) or intimal dissection
considered secondary to thrombectomy (n ¼ 9). No
differences in baseline and procedural characteristics
were observed between patients with classiﬁed
versus unclassiﬁed culprit plaques except for the rate
of thrombus at presentation (81.4% vs. 96.8%; p ¼
0.04) (12). Hence, a fully identiﬁable culprit plaque
morphology was adjudicated in 97 patients, with RFC
identiﬁed in 63 (64.9%), IFC in 32 (33.0%), and
spontaneous dissection in 2 (2.1%). There were no
signiﬁcant differences between RFC and IFC groups
in demographic factors, risk factors, and clinical
history (Table 1). However, patients with IFC pre-
sented more frequently with an open IRA (Throm-
bolysis In Myocardial Infarction [TIMI] ﬂow grade
of 2 or 3: 56.2% IFC vs. 34.9% RFC; p ¼ 0.047)
(Table 2). Baseline lesion severity was not signiﬁ-
cantly different (percentage of diameter stenosis,
88% IFC vs. 100% RFC; p ¼ 0.54). Although the
ﬁnal TIMI ﬂow grade was similar between groups
(TIMI ﬂow grade 3 >95% in both), patients with
IFC had a lower peak level of creatine kinase-
myocardial band (66.6 IU/l vs. 149.8 IU/l, p ¼
0.025). No difference in the type of antiplatelet
agent was observed in patients with IFC versus RFC
(clopidogrel, 84.4% IFC vs. 79.4% RFC; prasugrel,
15.6% IFC vs. 20.6% RFC; p ¼ 0.56).
BASELINE OCT. The OCT analysis showed that IFC
had residual thrombus less frequently before stent
implantation (84.4% vs. 98.4%, p ¼ 0.016) and
lower volumes of both white (0.41 mm3 vs. 1.52 mm3;
p ¼ 0.001) and red thrombus (0 mm3 vs. 0.29 mm3;
p ¼ 0.001), but a similar minimal lumen area (mean
1.27 mm2 vs. 1.17 mm2; p ¼ 0.91) (Table 3). Further, IFC
had fewer lipid areas (75% vs. 100%; p < 0.001) and
more ﬁbrotic areas (25.0% vs. 0.0%; p ¼ 0.005) at
the culprit site. The incidence of any additional
TCFA along the IRA was signiﬁcantly lower in patients
with IFC compared with those with RFC (46.9% vs.
93.7%; p < 0.001).
TABLE 3 Optical Coherence Tomography Analysis
IFC
(n ¼ 32)
RFC
(n ¼ 63) p Value
Pre–stent implantation
Proximal reference area, mm2 7.66 (5.89–11.42) 7.37 (5.96–9.96) 0.59
Distal reference area, mm2 5.46 (4.04–8.65) 5.97 (4.46–8.61) 0.58
Minimal lumen area, mm2 1.27 (1.21–1.55) 1.17 (0.93–1.67) 0.91
Culprit plaque components, %
Calciﬁed 0.0 (0.0–25.0) 0.0 (0.0–0.0) 0.08
Fibrotic 25.0 (0.0–43.8) 0.0 (0.0–0.0) 0.005
Lipid rich 75.0 (25.0–75.0) 100 (75.0–100.0) <0.001
Normal 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.057
Mean ﬁbrous cap thickness at culprit site, mm 203 (176.0–252.0) 171 (150.0–215.0) 0.0017
Minimal ﬁbrous cap thickness at culprit site, mm 69 (51–77) 47 (38–48) <0.001
Thrombus presence 27 (84.4) 62 (98.4) 0.016
White thrombus
Presence 25 (78.1) 62 (98.4) 0.002
Volume, mm3 0.41 (0.03–1.85) 1.52 (0.69–3.20) 0.001
Red thrombus
Presence 14 (43.8) 36 (57.1) 0.22
Volume, mm3 0.00 (0.00–2.76) 0.29 (0.00–1.31) 0.001
TCFA along the culprit vessel* 15 (46.9) 59 (93.7) <0.001
Mean cap thickness, mm 49.4 (46.4–51.0) 50.9 (48.3–54.3) 0.13
Post–stent implantation† 31 62
Mean stent area, mm3 7.04 (5.65–10.36) 7.19 (5.65–9.44) 0.82
Stent expansion index 82.8 (77.1–88.3) 83.0 (76.7–87.5) 0.68
% Protrusion volume 7.4 (4.0–14.5) 9.1 (5.5–13.7) 0.07
Mean malapposition area, mm2 0.07 (0.03–0.22) 0.09 (0.03–0.25) 0.62
9-month follow-up 27 57
Frame level analysis
Minimal stent area, mm2 5.89 (4.50–9.12) 6.18 (4.60–7.96) 0.81
Minimal lumen area, mm2 4.57 (3.09–7.36) 5.39 (3.38–6.79) 0.81
Mean NIH area, mm2 0.87 (0.50–1.17) 0.70 (0.42–1.11) 0.28
Volume obstruction, % 12.6 (5.4–20.8) 10.2 (6.1–15.3) 0.27
Mean malapposition area, mm2 0.14 (0.00–0.19) 0.02 (0.00–0.18) 0.58
Strut level analysis
Total analyzed struts/patients 161 (113–196) 138 (114–220) 0.99
Covered struts, % 92.5 (82.4–99.5) 91.2 (81.7–96.3) 0.15
Malapposed struts, % 0.3 (0.0–5.1) 0.6 (0.0–4.6) 0.88
Mean NIH area, mm2 101 (57–152) 97 (58–126) 0.28
Values are median (interquartile range), n (%), or n. *Number of TCFAs observed along the scanned segment into the culprit vessel, outside the culprit lesion. †No differences
were observed between IFC and RFC in terms of not analyzed frames and struts, both post-stenting and at 9-month follow-up (data not reported).
NIH ¼ neointimal hyperplasia; TCFA ¼ thin-cap ﬁbroatheroma; other abbreviations as in Table 1.
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571THROMBUS AND BIOMARKER ANALYSIS. Consistent
with OCT ﬁndings, thrombus aspirates of sufﬁcient
amount for histology analysis were retrieved less
frequently in patients with IFC (40.6% vs. 66.7%;
p ¼ 0.015), but there were no signiﬁcant differ-
ences in thrombus components, inﬂammation scores,
and thrombus age between groups (Table 4). The
presence of plaque material was signiﬁcantly lower
in the IFC group (7.1% vs. 54.8%; p ¼ 0.003). Immu-
nohistochemistry did not show signiﬁcant differences
between IFC and RFC, with the notable exception of
a higher amount of eosinophils in the IFC group(interleukin-5: 5 high-power ﬁelds, 1 [0 to 1] vs. 0 [0 to
1]; p ¼ 0.01). There were no signiﬁcant differences
between groups in the analyzed blood biomarkers
of inﬂammation and platelet activation (Table 4).
ACUTE RESULTS AND CLINICAL OUTCOMES. The
acute results of primary PCI with the EES were
also comparable between groups (Tables 2 and 3). At
9-month follow-up, the stent parameters were not
signiﬁcantly different between groups. Importantly,
independent of the lesion morphology, we observed
low levels of neointima obstruction, high rates of
TABLE 4 Histopathology and Immunohistochemistry of Aspirated Thrombus and
Blood Biomarkers
IFC
(n ¼ 32)
RFC
(n ¼ 63) p Value
Analyzed thrombus 13 (40.6) 42 (66.7) 0.015
Thrombus volume, mm3 9 (2–15) 6 (3–25) 0.47
Thrombus age 1.00
Early 10 (76.9) 32 (76.2)
Organized 3 (23.1) 10 (23.8)
Platelet presence 13 (100) 42 (100) 1.00
Average WBCs, cells/5HPF 75 (50–250) 75 (75–200) 0.96
Inﬂammation score 1.0 (1.0–2.5) 1.0 (1.0–2.0) 0.91
Plaque material 1 (7.7) 23 (54.8) 0.003
Immunohistochemistry
MPO, cells/5HPF 46 (17–86) 43 (30–104) 0.73
CD68, cells/5HPF 15 (7–28) 20 (15–50) 0.12
IL-5, cells/5HPF 1 (0–1) 0 (0–1) 0.01
CD42b, score 2 (2–2.5) 2 (2–3) 0.98
Blood biomarkers 27 60
hsCRP, mg/l 1.72 (1.02–3.49) 2.10 (0.79–4.93) 0.72
ECP, ng/ml 3.69 (2.00–9.40) 4.80 (2.70–9.62) 0.36
TXB2, pg/ml 93.2 (53.0–214.8) 134.8 (57.7–295.9) 0.19
MPO, mg/l 526.2 (289.5–905.8) 649.3 (300.0–1,695.0) 0.34
Values are n (%), median (interquartile range), or n.
ECP ¼ eosinophil cationic protein; hsCRP ¼ high-sensitivity C-reactive protein; MPO ¼ myeloperoxidase; IL ¼
interleukin; TXB2 ¼ thromboxane B2; 5HPF ¼ 5 high-power ﬁelds (400); WBCs ¼ white blood cells; other
abbreviations as in Table 1.
TABLE 5 Clinical Outcomes
IFC
(n ¼ 32)
RFC
(n ¼ 63) p Value
30 days
MACCE 2 (6.2) 1 (1.6) 0.26
Death 1 (3.1) 0 (0.0) 0.34
Cardiac 1 (3.1) 0 (0.0) 0.34
Noncardiac 0 (0.0) 0 (0.0) 1.00
Reinfarction 0 (0.0) 1 (1.6) 1.00
Stroke 1 (3.1) 0 (0.0) 0.34
Stent thrombosis 0 (0.0) 1 (1.6) 1.00
Deﬁnite 0 (0.0) 1 (1.6) 1.00
Probable 0 (0.0) 0 (0.0) 1.00
Ischemia-driven TLR 0 (0.0) 1 (1.6) 1.00
Target vessel revascularization 0 (0.0) 1 (1.6) 1.00
1 Year
MACCE 3 (9.4) 4 (6.3) 0.68
Death 3 (9.4) 2 (3.2) 0.33
Cardiac 2 (6.4) 0 (0.0) 0.11
Noncardiac 1 (3.1) 2 (3.2) 1.00
Reinfarction 0 (0.0) 1 (1.6) 1.00
Stroke 1 (3.1) 0 (0.0) 0.34
Stent thrombosis 0 (0.0) 1 (1.6) 1.00
Deﬁnite 0 (0.0) 1 (1.6) 1.00
Probable 0 (0.0) 0 (0.0) 1.00
Ischemia-driven TLR 0 (0.0) 4 (6.3) 0.30
Target vessel revascularization 1 (3.1) 7 (11.1) 0.26
Values are n (%).
MACCE ¼ major adverse cardiac or cerebrovascular events; TLR ¼ target lesion revascularization; other
abbreviations as in Table 1.
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572strut coverage, and minimal rates of late malap-
position (Table 3). At 1- and 2-year follow-up, the
incidence of major adverse cardiac or cerebrovascular
events was low, without statistically signiﬁcant dif-
ferences between the 2 study groups (Table 5,
Figure 2). Stent thrombosis (subacute) occurred in
only 1 patient in the RFC group.
DISCUSSION
The principal ﬁndings of this study are the
following. 1) An IFC was present in the culprit lesion
in one-third of the cases of STEMI investigated
in vivo. 2) The morphology of the culprit plaque was
not associated with speciﬁc clinical factors or bio-
logical markers. 3) Compared with RFC, IFC pre-
sented more frequently with a patent IRA and was
associated with fewer lipid areas, lower frequency of
additional TCFAs along the culprit vessel, less
thrombus presence and amount, and a lower crea-
tine kinase-myocardial band peak post-PCI. 4) There
were no major differences in acute and chronic
vascular response to PCI with current-generation
EES in patients with different culprit plaque
morphology.
First, in our study that included patients of all
ages and considered only culprit plaques with a
clearly identiﬁed morphology, the incidence of IFC
was 33%, whereas RFC was observed in 64.9%. This
observation is consistent with pathology series and
smaller OCT studies (3,6,10,19). Calciﬁed nodules,
i.e., nodular calciﬁcations protruding into the lumen
and described as a rare cause of coronary throm-
bosis in autopsy series, were not identiﬁed in our
series. A plausible explanation can be found in the
exclusion of patients with heavily calciﬁed and
tortuous coronary arteries (12), which are more
likely to present calciﬁed nodules (3). Nevertheless,
our ﬁndings are consistent with no evidence of
calciﬁed nodules as culprit plaque in STEMI patients
reported in vivo by others using OCT (20). In
addition, calciﬁc nodules were not shown to be
related to future cardiovascular events in the pro-
spective PROSPECT (Providing Regional Observa-
tions to Study Predictors of Events in the Coronary
Tree) study (21).
Second, we compared clinical characteristics and
blood biomarkers between patients with IFC and
those with RFC and found no signiﬁcant difference
in all analyzed parameters (Tables 1 and 4). Plaque
erosion has been observed in ex vivo studies more
frequently in females and young individuals (3,6). In
the main report from the OCTAVIA trial, we found
that, when age matched, STEMI men and women did
FIGURE 2 Event-Free Survival According to
Culprit Plaque Morphology
Survival free from major adverse cardiac or cerebrovascular
events (MACCE). IFC ¼ intact ﬁbrous cap; RFC ¼ ruptured ﬁbrous
cap.
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573not show different mechanisms of coronary throm-
bosis (12). Similar ﬁndings were recently reported by
Jia et al. (20).
Previous studies found higher levels of serum MPO
in patients with IFC compared with those with RFC,
raising the hypothesis that increases in selective
inﬂammatory biomarkers might be associated with
different plaque morphologies (22). In our study, we
did not observe signiﬁcant differences in blood
biomarkers of inﬂammation and platelet activation
between patients with IFC and RFC, including MPO,
suggesting that patient selection biases may be
responsible for many of the observed discrepancies
across studies (3).
Third, the presence of endoluminal thrombus
initially detected by OCT at the culprit site was high
in both groups but signiﬁcantly lower in IFC
compared with RFC, with less residual white and red
clot volume after thrombus aspiration in the IFC
group (Table 3). This is not surprising because in
RFC, the exposed necrotic core is highly thrombo-
genic (3,23). The lower thrombus burden in IFC may
explain the lower creatine kinase-myocardial band
peak compared with patients with RFC, a ﬁnding
consistent with previous intravascular ultrasound
studies demonstrating larger infarct size in patientswith evidence of plaque rupture as opposed to
different plaque phenotypes (24,25). The composi-
tion of aspirated thrombi was similar between
groups (Table 4), whereas less plaque material was
retrieved in patients with IFC. This feature is
consistent with the lower lipid content of eroded
plaques observed by OCT both at the culprit site and
along the IRA, combined with less TCFA. Immuno-
histochemistry analysis of aspirated thrombi showed
only a slightly higher yet statistically signiﬁcant
different number of eosinophils, marked with
interleukin-5, in association with eroded plaque.
This observation may suggest an activation of
eosinophils in a subset of patients with IFC, favoring
thrombus growth even in the absence of plaque
rupture due to the strong prothrombotic activity of
eosinophilic granules (26).
Fourth, an important ﬁnding of our study is that
there was not a signiﬁcantly different vascular
response to the EES between groups. Indeed, quan-
titative coronary analysis and OCT parameters at
9-month follow-up were very similar, including late
lumen loss, diameter stenosis, neointimal area, stent
strut coverage, and malapposition (Tables 2 and 3).
Whether plaque morphology underlying STEMI
should lead to a different therapeutic approach re-
mains speculative. Previous studies suggested that
OCT may identify patients with eroded, subcritically
occlusive plaque that can be treated with thrombec-
tomy alone without stenting (4,5). In the present
study, IFC and RFC showed similar degrees of ste-
nosis and a high incidence of residual endoluminal
thrombus after manual thrombectomy, raising doubts
about a different treatment strategy. Furthermore,
vascular response to the EES was excellent and
similar in both groups.
STUDY LIMITATIONS. First, the population enrolled
was not representative of a high-risk STEMI cohort,
and a number of patients could not be included.
The study was, in fact, designed to avoid any un-
necessary delay due to OCT pullback before res-
toring myocardial reperfusion, and patients were
not enrolled if good coronary ﬂow could not be
obtained with thrombus aspiration only. Second,
24% of lesions had indeterminate morphology on
OCT. However, this was essentially due to the strict
quality criteria applied by the OCT core laboratory,
and comparable rates were found by other authors
(20). Third, the extent to which OCT can identify
all features recognized by pathology remains to be
veriﬁed. Although the identiﬁcation of RFC with OCT
has a high level of evidence (13), IFC can be classiﬁed
with a lower level of conﬁdence, and its deﬁnition is
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
most common culprit plaque phenotype in STEMI is a
lipid-rich plaque with RFC. Plaque erosion, i.e., coro-
nary thrombosis in the presence of a plaque with
an IFC, accounts for one-third of the cases. Appar-
ently, there is no signiﬁcant association of plaque
morphology with clinical factors or standard markers
of inﬂammation and platelet activation. IFC seems to
be associated with higher rates of a patent IRA at ﬁrst
angiography, fewer lipid areas, and less endoluminal
thrombus. However, no difference in vascular
response to current-generation drug-eluting stents
has been observed.
TRANSLATIONAL OUTLOOK: The best treatment
for STEMI is rapid ﬂow restoration with primary an-
gioplasty and stenting, preferably with drug-eluting
stents. In this setting, the potential impact of
different culprit plaque characteristics is a matter of
debate because different plaque morphologies might
be amenable to different treatments. Further studies
are necessary to better delineate the mechanisms of
atherothrombosis in STEMI and to test the potential
role of a tailored approach based on different culprit
plaque phenotypes.
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574still debated. Fourth, OCT criteria for quantitative
measurement of red thrombus have not been fully
validated, and relative data should be interpreted
cautiously. Finally, the sample sizewas underpowered
for clinical endpoints, and comparison between the
2 study groups reported in Table 5 has only a descrip-
tive purpose.
CONCLUSIONS
In the present study, an IFC consistent with plaque
erosion was observed at the culprit lesion site in one-
third of patients with STEMI. IFC compared with
RFC was associated with higher rates of patent IRA
at ﬁrst angiography, fewer lipid areas, and endolu-
minal thrombus. However, no difference in vascular
response to EES was observed.
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